Lilly launches insulin pens and glucagon injectibles
Lilly launches insulin pens and glucagon injectibles
Eli Lilly and Co. of Indianapolis has launched two new products important to diabetes management.
Recombinant glucagon for use in severe hypoglycemic events has replaced the company’s animal-source glucagon product and was expected to be available in pharmacies in March.
The Humulin 70/30 (70% human insulin isophane suspension, 30% human insulin), Humulin N, and Humalog injections are intended to simplify insulin delivery.
The pre-filled disposable pens hold 300 units of insulin. No refrigeration is necessary after the first use. The pocket-sized pen has a magnified dosage window to dispense precise quantities of insulin. It’s designed to improve glycemic control in patients with irregular schedules.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.